[
    {
        "image": "s3://doc-parse-huawei/mineru2/inhouse-markdown/zh-10-M/v001/images/6d09419702edabb65a877898eb62e06b/220.jpg",
        "conversations": [
            {
                "from": "human",
                "value": "<Mineru-Image>\nGrouding with reading order: "
            },
            {
                "from": "gpt",
                "value": "\n<|box_start|>089 123 420 147<|box_end|><|ref_start|>text<|ref_end|><|md_start|>却已死去!仙枣想已泻出了!<|md_end|>\n<|box_start|>089 153 916 680<|box_end|><|ref_start|>text<|ref_end|><|md_start|>武帝还疑他尸解成仙\"很加叹息!可巧来了一个齐人少翁\"也与少君一般论调\"正好继续少君\"说鬼谈仙!适值武帝宠姬王夫人\"得病身亡\"王夫人有子名闳\"由王夫人病重时\"以子相托!时武帝长子据\"已册为太子\"即卫皇后所生!闳当然不能立储\"只好许为齐王!王夫人却也道谢!至王夫人死后\"武帝追忆不忘\"少翁即自言能致鬼魂相见如少时!武帝甚喜\"便命少翁作起法来\"少翁命腾出净室\"四周张帷\"并索取王夫人生前衣服\"预备招魂!到了夜间\"在帷外o起灯烛\"使武帝独坐待着\"自己走入帷中\"东喷水\"西念咒\"闹了两三个时辰\"果有一个美貌女子\"被他引至!武帝正向帷中痴望\"见了这般美妇人\"不觉出神\"凝睇审视\"身材等确与王夫人无二!急欲入帷与语\"却被少翁出帷阻住\"转眼一看\"美人儿已没有了!逐句写来\"情伪毕露!武帝特作词寄感\"列入乐府\"词云#\\$是耶非耶%立而望之\"翩何姗姗其来迟&’语意原是约略模糊\"并非确见\"但尚拜他为文成将军\"待以客礼\"令他求仙!要他求仙亦不应封为将军!<|md_end|>\n<|box_start|>089 684 916 945<|box_end|><|ref_start|>text<|ref_end|><|md_start|>少翁乃请在甘泉宫中\"增筑台观\"绘塑许多奇形怪状的 偶像\"或称天神\"或称地+\"或称为泰一神!泰一两字\"源 出古书\"大约作上天的解释!当时燕齐方士\"竞称天神\"最 贵要算泰一\"五帝尚是泰一的佐使\"故泰一当首先供奉!少 翁也主此说\"武帝方深信少翁\"但教少翁如何主张\"无不照 办!无如神仙杳远\"始终不肯光临\"武帝也有些疑心起来!一 日至甘泉宫\"访问少翁\"忽有一人牵过一牛\"少翁便指示武 帝道#\\$这牛腹中当有奇书!’武帝乃命左右将牛牵住\"立刻<|md_end|>"
            }
        ]
    },
    {
        "image": "s3://doc-parse-huawei/mineru2/inhouse-markdown/zh-10-M/v001/images/ae4a42a393dacb174b3a001160627cac/531.jpg",
        "conversations": [
            {
                "from": "human",
                "value": "<Mineru-Image>\nGrouding with reading order: "
            },
            {
                "from": "gpt",
                "value": "\n<|box_start|>124 093 874 144<|box_end|><|ref_start|>text<|ref_end|><|md_start|>子突然不争气地“咕”了一声，这才想起来自从离开南京之后，还没怎么正经坐下来吃东西。<|md_end|>\n<|box_start|>124 169 874 249<|box_end|><|ref_start|>text<|ref_end|><|md_start|>旁边苏荆溪耳朵略一歪，开口道：“我有些饿了，先吃些东西吧。”于谦觉得在外面吃饭有些太招摇，可朱瞻基已抢先道：“好，先填饱肚子再说别的！”<|md_end|>\n<|box_start|>126 274 874 323<|box_end|><|ref_start|>text<|ref_end|><|md_start|>于谦跟吴定缘低声商量了一下，决定先让吴定缘去找个当铺，拿合浦珠子换些散碎银两与宝钞，方便开销，其他人则找个食肆歇脚。<|md_end|>\n<|box_start|>126 348 874 457<|box_end|><|ref_start|>text<|ref_end|><|md_start|>去哪里吃，却是个问题。于谦和苏荆溪都听太子的，可朱瞻基瞧了半天招牌，眼睛都快花了，不知该怎么取舍才好。于谦笑道：“淮安这里是南北分界，所以口味最杂，米面兼备，鱼羊皆有。殿下尽可以随口味来选。”<|md_end|>\n<|box_start|>124 481 874 591<|box_end|><|ref_start|>text<|ref_end|><|md_start|>听了于谦提醒，朱瞻基这才发现，石路两侧的招摇旗幌里，不乏火烧、扁食、蒜面、秃秃麻食等字样，这都是北方才有的吃食。他毕竟生长于京城，虽然江南饮食精致细腻，可肚子一旦真饿起来，非面食不足以抚慰。<|md_end|>\n<|box_start|>181 615 533 638<|box_end|><|ref_start|>title<|ref_end|><|md_start|># “咱们就去……吃一碗蒜面吧！”<|md_end|>\n<|box_start|>126 662 874 712<|box_end|><|ref_start|>text<|ref_end|><|md_start|>朱瞻基终于下定了决心。这玩意在京城夏天颇为流行，可惜身为太子，吃一嘴蒜臭有失体面，宫里很少能吃到。<|md_end|>\n<|box_start|>124 737 876 903<|box_end|><|ref_start|>text<|ref_end|><|md_start|>于是，他们径直去了一处还算干净的面铺。面铺不大，里头只摆着七八张木桌，不过装潢却颇有味道，墙壁粉白，上头还题着一首诗：“家在枚皋旧宅边，竹轩晴与楚坡连，芰荷香绕垂鞭袖，杨柳风横弄笛船。城碍十洲烟岛路，寺临千顷夕阳川。可怜时节堪归去，花落猿啼又一年。”——乃是晚唐名家赵承佑的《忆山阳》。于谦读罢，赞叹不已，连引车卖浆之流都这等好品位，淮安果然文教深厚。<|md_end|>"
            }
        ]
    },
    {
        "image": "s3://doc-parse-huawei/mineru2/inhouse-markdown/zh-10-M/v001/images/071a65b79400f6147058f46c552b213b/217.jpg",
        "conversations": [
            {
                "from": "human",
                "value": "<Mineru-Image>\nGrouding with reading order: "
            },
            {
                "from": "gpt",
                "value": "\n<|box_start|>119 146 601 571<|box_end|><|ref_start|>image<|ref_end|><|md_start|>![]('img_url')<|md_end|>\n<|box_start|>123 606 877 718<|box_end|><|ref_start|>text<|ref_end|><|md_start|>他走啊走啊，来到了城堡前。他敲了敲门，又喊了几声，但没有人答应。他索性直接走进去，在各个房间都转了一圈，可还是一个人都没有看到。最后，在那个最华丽的房间里，他看见一个漂亮的少女睡在一张天鹅绒沙发上。<|md_end|>\n<|box_start|>123 732 877 814<|box_end|><|ref_start|>text<|ref_end|><|md_start|>士兵慢慢走近女孩，但她仍然在沉睡。她脚上套着的一只拖鞋掉在了地上，士兵把它捡起来放进口袋里。他亲吻了一下女孩，随后踮着脚尖悄声离开了。<|md_end|>\n<|box_start|>124 830 876 883<|box_end|><|ref_start|>text<|ref_end|><|md_start|>他刚离开，女孩就醒了过来，喊侍女们进房间。她们在隔壁房间里，和这里其他的人一样，都陷入了长眠。侍女们随之醒来后，赶紧<|md_end|>"
            }
        ]
    },
    {
        "image": "s3://doc-parse-huawei/mineru2/inhouse-markdown/en-10-M/v001/images/c781071c04721063d37e8e4fd24e92be/4.jpg",
        "conversations": [
            {
                "from": "human",
                "value": "<Mineru-Image>\nGrouding with reading order: "
            },
            {
                "from": "gpt",
                "value": "\n<|box_start|>098 064 503 124<|box_end|><|ref_start|>text<|ref_end|><|md_start|>the reverse was true. In the following presentation of the pharmacokinetic data, a special effort has been made to identify any feature of the profiles that correlates with toxicity.<|md_end|>\n<|box_start|>098 125 503 335<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Fig. 2 shows \\(C_{\\mathrm{max}}\\) , \\(t_{1/2}\\) and AUC for all patients on each day of assessment. All the values available from an individual patient are joined by a line to illustrate the changing patterns. The patients are ordered according to the maximum degree of nausea and vomiting they experienced, with the most severe toxicity being on the left side of the diagram. There was no clear correlation of higher peak levels, longer half-lives or greater areas under the curve for those patients exhibiting toxicity compared to those patients who experienced none. Indeed, one of the patients presenting with severe nausea and vomiting had a very low peak level and a normal half-life, whereas one patient with a very high peak level and very long half-life suffered only a grade 1 toxicity on one of the four occasions.<|md_end|>\n<|box_start|>098 337 503 516<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Fig. 2a shows that on all occasions the peak levels were above the target value of \\(600{-}700\\,\\mathrm{nmol/ml}\\) and indeed were generally considerably higher. The minimum, maximum, mean, median and errors of these values are summarized in Table 2. The peaks were usually achieved at 1 or \\(2\\,\\mathrm{{h}}\\) (see Table 1). The variation between patients was no larger than the variation within patients. The pattern of increasing or decreasing peak levels at the start and end of each course can be seen to be equally represented. Two patients showed very dramatic accumulation at the end of their second course of radiotherapy, one accompanied by moderate nausea and the other being asymptomatic.<|md_end|>\n<|box_start|>099 517 503 620<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Fig. 2b illustrates the wide range of values for \\(t_{1/2}\\) , both within and between patients. All of the four extremely high values were for the last dose in the protracted series and may be associated with progressive accumulation over a period of several days because of slower excretion. Three of the four lowest values were for the first dose in the series. There was no trend in the toxicity ranking of the patients.<|md_end|>\n<|box_start|>099 623 503 757<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Fig. 2c shows the equivalent plot for AUC for each profile. A similar wide variation was seen in this parameter and the correlation between toxicity ranking and AUC is very weak. One of the patients experiencing mild toxicity and one patient experiencing almost no toxicity showed the highest values for AUC. Thus, no clear pattern emerges of the cause of nausea and vomiting in some patients but not in others. There is no clear threshold dose of nicotinamide or an excretion rate that can guarantee an absence of toxicity.<|md_end|>\n<|box_start|>098 758 503 908<|box_end|><|ref_start|>text<|ref_end|><|md_start|>One of the important aspects of this study was to find the optimum time for administration of nicotinamide before radiotherapy. In Table 1, the time to the peak concentration can be seen to vary widely between 1 and \\(^\\textrm{\\scriptsize6h}\\) . However, since peak levels well above the target for radiosensitization were achieved, the desirable interval can be concealed by this \\(T_{\\mathrm{max}}\\) estimate. The actual levels achieved 1, 2, 4, 6 and 8 \\(_\\mathrm{h}\\) after ingestion are shown in Fig. 3. The figures at the bottom indicate the fraction of the patients who did not exceed the target level at each time. By \\(1\\,\\mathrm{~h~}\\) only \\(8\\%\\) of<|md_end|>\n<|box_start|>546 066 936 625<|box_end|><|ref_start|>image<|ref_end|><|md_start|>![]('img_url')<|md_end|>\n<|box_start|>541 636 946 748<|box_end|><|ref_start|>image_caption<|ref_end|><|md_start|>Fig. 2. Pharmacokinetic characteristics of each patient at sequential assessments. This figure illustrates the range of values from patient to patient and the pattern within each patient at different points within their treatment course. The patients are ranked according to the maximum toxicity score they experienced (indicated as grades, $\\mathrm{Gd}\\ 0{-}3)$ ). There was a five- to sixfold variation in all these parameters, but there was no systematic trend with toxicity grade. (a) Peak concentration of nicotinamide in plasma. (b) Half-life of nicotinamide. (c) AUC calculated from the profile using the Bateman model $(\\mathrm{nmol}/\\mathrm{ml})$ per h).<|md_end|>\n<|box_start|>543 758 946 847<|box_end|><|ref_start|>text<|ref_end|><|md_start|>the values were below \\(700\\;\\mathrm{nmol/ml}\\) and by \\(2\\,\\mathrm{{h}}\\) all the values were above this level. In schedules using two fractions per day, the second irradiation would be after a \\(4\\,\\mathrm{{h}}\\) interval, i.e. \\(^\\textrm{\\scriptsize5h}\\) after ingesting nicotinamide. At this time, between 13 and \\(33\\%\\) of the values would have fallen below the peak due to those patients with short half-lives.<|md_end|>\n<|box_start|>543 849 946 908<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Fig. 4 shows the spectrum of peak values for the parent compound and the four major metabolites as a cumulative plot. It demonstrates that the median value was \\(1166~\\mathrm{nmol}/\\) ml for the peak concentration and around 65, 64, 30 and 9<|md_end|>"
            }
        ]
    },
    {
        "image": "s3://doc-parse-huawei/mineru2/inhouse-markdown/zh-10-M/v001/images/d1ee2389ecddea725c7103197557b3a8/0.jpg",
        "conversations": [
            {
                "from": "human",
                "value": "<Mineru-Image>\nGrouding with reading order: "
            },
            {
                "from": "gpt",
                "value": "\n<|box_start|>067 118 620 145<|box_end|><|ref_start|>text<|ref_end|><|md_start|>金融工程报告 数量化选股策略 2016 年5 月3 日<|md_end|>\n<|box_start|>072 182 376 205<|box_end|><|ref_start|>title<|ref_end|><|md_start|># 个股特征研究策略之二<|md_end|>\n<|box_start|>071 214 516 240<|box_end|><|ref_start|>title<|ref_end|><|md_start|># -基于个股持续性的指数增强策略<|md_end|>\n<|box_start|>071 247 161 262<|box_end|><|ref_start|>title<|ref_end|><|md_start|># 核心观点:<|md_end|>\n<|box_start|>121 274 196 290<|box_end|><|ref_start|>title<|ref_end|><|md_start|># 报告逻辑<|md_end|>\n<|box_start|>124 293 610 339<|box_end|><|ref_start|>text<|ref_end|><|md_start|>个股既是独立的个体，又与指数的涨跌息息相关。报告从两个方面的统计出发，描述个股的市场跟随性和自身效应，以形成短线选股指标用于指数增强。<|md_end|>\n<|box_start|>652 280 704 294<|box_end|><|ref_start|>title<|ref_end|><|md_start|># 分析师<|md_end|>\n<|box_start|>650 305 893 362<|box_end|><|ref_start|>text<|ref_end|><|md_start|>王红兵：0755-83479312：wanghongbing_yj@chinastock.com.cn执业证书编号：S0130514060001<|md_end|>\n<|box_start|>091 363 225 377<|box_end|><|ref_start|>title<|ref_end|><|md_start|># 策略主要思路<|md_end|>\n<|box_start|>121 382 610 518<|box_end|><|ref_start|>text<|ref_end|><|md_start|>本报告提出当个股上涨天数和跟随市场天数在统计极值附近的时候会发生反转，我们将利用这个反转效应进行选股。市场跟随类指标：指数前一日涨跌幅与个股当天涨跌幅方向的相关性，如果是同向，说明个股跟随市场走势。反之则反向。个股自身效应类指标：个股持续上涨/下跌天数累加。当以上两个指标达到阀值时，我们将认为个股会反转：比如个股下跌天数达到阀值并且不跟随市场天数达到阀值，它大概率自身会反弹，并且跟随市场上涨。<|md_end|>\n<|box_start|>650 380 846 437<|box_end|><|ref_start|>text<|ref_end|><|md_start|>黎鹏：0755-83471683：lipeng_yj@chinastock.com.cn执业证书编号：S0130514070001<|md_end|>\n<|box_start|>650 469 722 483<|box_end|><|ref_start|>title<|ref_end|><|md_start|># 相关研究<|md_end|>\n<|box_start|>650 485 930 512<|box_end|><|ref_start|>text<|ref_end|><|md_start|>《个股特征研究策略之一-基于个股领先方向性的大盘择时策略》<|md_end|>\n<|box_start|>096 540 195 554<|box_end|><|ref_start|>title<|ref_end|><|md_start|># 策略效果<|md_end|>\n<|box_start|>121 559 608 635<|box_end|><|ref_start|>text<|ref_end|><|md_start|>指标用于全业绩链策略的改进，改进后的效果为：年度平均收益为 \\(47\\%\\) ，最大回撤为 \\(10\\%\\) ，月度胜率为 \\(66\\%\\) 。指标用于税费策略的改进，改进后的效果为：年度平均收益为 \\(16\\%\\) ，最大回撤为\\(8\\%\\) ，月度胜率为 \\(65\\%\\) 。以上两个策略使用本报告指标后每年均有\\(5\\mathrm{-}10\\%\\) 的提升。<|md_end|>"
            }
        ]
    },
    {
        "image": "s3://doc-parse-huawei/mineru2/inhouse-markdown/en-10-M/v001/images/0e2818624c9a2fa8d8781d562c289c40/18.jpg",
        "conversations": [
            {
                "from": "human",
                "value": "<Mineru-Image>\nGrouding with reading order: "
            },
            {
                "from": "gpt",
                "value": "\n<|box_start|>095 094 903 894<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Casella, A. (1992) ‘On Markets and Clubs: Economic and Political Integration of Regions with Unequal Productivity’. American Economic Review, Vol. 82, pp. 115–21. Casella, A. and Frey, B. (1992) ‘Federalism and Clubs. Towards An Economic Theory of Overlapping Political Jurisdictions’. European Economic Review,  Vol. 36, pp. 639–46. Casella, A. and Weingast, B. R. (1995) ‘Elements of a Theory of Jurisdictional Change’. In Eichengreen, B., Frieden, J. and von Hagen, J. (eds) Politics and Institutions in an Integrated Europe (New York/Heidelberg: Springer), pp. 11–41. Downs, A. (1957) An Economic Theory of Democracy (New York: Harper & Row). Falkner, G. (1999) ‘Corporatist Governance and Europeanisation: No Future in the Multi-level Game?’ Current Politics and Economics of Europe , Vol. 8, pp. 387– 412. Frey, B. and Eichenberger, R. (1999) The New Democratic Federalism for Europe. Functional, Overlapping and Competing Jurisdictions (Cheltenham: Edward Elgar). Friedman, D. (1977) ‘A Theory of the Size and Shape of Nations’. Journal of Political Economy, Vol. 85, pp. 59–77. Gray, V. (1973) ‘Innovation in the States: A Diffusion Study’. American Political Science Review, Vol. 67, pp. 1174–85. Hinich, M. and Munger, M. (1994) Ideology and the Theory of Political Choice (Ann Arbor: University of Michigan Press). Hooghe, L. (ed.) (1996) Cohesion Policy and European Integration: Building MultiLevel Governance (Oxford: Oxford University Press). Hooghe, L. and Marks, G. (1999) ‘Making of a Polity: The Struggle over European Integration’. In Kitschelt, H., Lange, P., Marks, G. and Stephens, J. (eds) (1999b), pp. 70–97. Hooghe, L. and Marks, G. (2001) European Integration and Multi-Level Governance (Boulder, CO: Rowman & Littlefield). Hooghe, L., Marks, G. and Wilson, C. (2000) ‘Party Positions on European Integration: New Politics versus Left/Right’. Paper presented at a workshop on ‘Dimensions of Contestation in the European Union’. University of North Carolina, Chapel Hill, 30 April–2 May. Inman, R. P. and Rubinfeld, D. (1992) ‘Fiscal Federalism in Europe: Lessons from the United States Experience’. European Economic Review,  Vol. 36, pp. 654–60. Inman, R. P. and Rubinfeld, D. (1997) ‘Making Sense of the Anti-trust State-Action Doctrine: Balancing Political Participation and Economic Efficiency in Regulatory Federalism’. Texas Law Review, Vol. 75, pp. 1203–99. Jachtenfuchs, M. and Kohler-Koch, B. (1995) ‘Regieren im dynamischen Mehrebenensystem’. In Jachtenfuchs, M. and Kohler-Koch, B. (eds) Europäische Integration (Opladen: Leske \\(^+\\) Budrich), pp. 15–44. Jeffery, C. (ed.) (1997) The Regional Dimension of the European Union: Towards a Third Level in Europe?  (London: Frank Cass). Jeffery, C. (2000) ‘Subnational Mobilization and European Integration: Does it Make Any Difference?”Journal of Common Market Studies, Vol. 38, No. 1, pp. 1–23.<|md_end|>"
            }
        ]
    },
    {
        "image": "s3://doc-parse-huawei/mineru2/inhouse-markdown/en-10-M/v001/images/44b302d9c0c771e4623bb0fbb456f790/27.jpg",
        "conversations": [
            {
                "from": "human",
                "value": "<Mineru-Image>\nGrouding with reading order: "
            },
            {
                "from": "gpt",
                "value": "\n<|box_start|>131 115 884 151<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Proof. Choose \\(V\\) to be a trace-class non-negative self-adjoint operator in the Hilbert space \\(H\\) such that<|md_end|>\n<|box_start|>392 156 616 194<|box_end|><|ref_start|>equation<|ref_end|><|md_start|>\\[\n\\bigvee_{\\mathrm{Im}\\;\\lambda\\ne0}(A-\\lambda)^{-1}V H=H.\n\\]<|md_end|>\n<|box_start|>131 200 500 216<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Clearly, such a choice is always possible.<|md_end|>\n<|box_start|>131 218 884 387<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Consider the functional model developed in [18] for the operators \\(L\\) admitting a representation \\(L_{\\varkappa}{=}A{+}\\alpha{\\varkappa}\\alpha/2\\) , where \\(\\alpha\\!\\geq\\!0\\) is a non-negative operator in the Hilbert space \\(H\\) and \\(\\varkappa\\) is a bounded operator in the subspace \\(E\\) , \\(E\\) being the closure of the range of \\(\\alpha\\) . Choose \\(\\alpha\\) to be a Hilbert–Schmidt class operator defined by the formula \\(\\alpha\\!=\\!\\sqrt{2V}\\!\\in\\!\\mathfrak{S}_{2}\\) . Then the operator \\(L_{\\varkappa}\\) is well defined on the domain \\(D(L_{\\varkappa})\\!=\\!D(A)\\) . Moreover, \\(L_{\\varkappa}\\!\\equiv\\!A\\) when \\(\\varkappa\\!=\\!0\\) , i.e., \\(L_{0}{\\equiv}A\\) . Consider the dissipative operator \\(L^{\\parallel}\\!\\equiv\\!A\\!+\\!i V\\) (this operator coincides with \\(L_{i I}\\) ). Clearly, it is a maximal dissipative operator in \\(H\\) ; moreover, it is easy to see that the condition (33) guarantees that it is also completely nonself-adjoint.<|md_end|>\n<|box_start|>131 387 884 463<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Construct the functional model based on the operator \\(L^{\\parallel}\\) (see Section 2 above). In the corresponding dilation space \\(\\mathcal{H}\\) the following formulae describe the action of the resolvent \\((A\\!-\\!\\lambda)^{-1}\\) on all vectors \\((\\widetilde{g},g)\\!\\in\\!K\\) , as above \\(K\\) being the model image of H (see [18]),<|md_end|>\n<|box_start|>183 454 834 544<|box_end|><|ref_start|>equation<|ref_end|><|md_start|>\\[\n\\begin{array}{r l r}&{\\cdots\\lefteqn{(A^{-\\backslash\\times}\\!\\!\\!\\!\\lambda^{-1\\slash\\jmath})^{\\prime}}}\\\\ &{}&{\\stackrel{\\displaystyle(A\\!-\\!\\!\\!\\lambda)^{-1}\\!\\!\\left(\\frac{\\tilde{g}}{g}\\right)=P_{K}\\frac{1}{(k-\\lambda)}\\binom{\\tilde{g}}{g-\\frac{1}{2}\\big(I\\!+\\!(S^{*}(\\overline{{\\lambda}})\\!-\\!I)\\frac{1}{2}\\big)^{-1}g_{-}(\\lambda)}\\Bigg),\\quad\\operatorname{Im}\\lambda\\!<\\!0,}\\\\ &{}&{\\quad\\quad(A\\!-\\!\\lambda)^{-1}\\binom{\\tilde{g}}{g}=P_{K}\\frac{1}{(k-\\lambda)}\\bigg(\\tilde{g}\\!-\\!\\frac{1}{2}\\big(I\\!+\\!(S(\\lambda)\\!-\\!I)\\frac{1}{2}\\big)^{-1}g_{+}(\\lambda)\\bigg),\\quad\\operatorname{Im}\\lambda\\!>\\!0.}\\end{array}\n\\]<|md_end|>\n<|box_start|>131 549 884 587<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Here \\(S(\\lambda)\\) is the characteristic function of the completely nonself-adjoint maximal dissipative operator \\(L^{\\parallel}\\) , all the other notation has already been introduced above.<|md_end|>\n<|box_start|>131 588 884 662<|box_end|><|ref_start|>text<|ref_end|><|md_start|>We introduce the following notation for the operator-valued functions, appearing in this representation: \\(\\Theta_{\\cal A}(\\lambda)\\!:=\\!I\\!+\\!({\\cal S}(\\lambda)\\!-\\!I){\\textstyle\\frac{1}{2}}\\) and \\(\\Theta_{A}^{\\prime}(\\lambda){:=}I\\!+\\!(S^{*}(\\overline{{{\\lambda}}})\\!-\\!I)\\frac{1}{2}\\) . The functions \\(\\Theta_{A}\\) and \\(\\Theta_{A}^{\\prime}\\) are bounded analytic operator-valued functions in the half-planes \\(\\mathbb{C}_{+}\\) and \\(\\mathbb{C}_{-}\\) , respectively.<|md_end|>\n<|box_start|>131 663 884 718<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Observe that the characteristic function \\(S(\\lambda)\\) is an inner operator-valued function in the upper half-plane. Indeed, it suffices to show that the boundary values of \\(S(\\lambda)\\) on the real axis are a.e.-unitary there. By the Hilbert identity,<|md_end|>\n<|box_start|>259 725 753 744<|box_end|><|ref_start|>equation<|ref_end|><|md_start|>\\[\nS^{*}(\\lambda)S(\\lambda)\\!-\\!I\\!=\\!\\Theta_{A}^{\\prime}(\\overline{{{\\lambda}}})\\alpha[(A\\!-\\!\\lambda)^{-1}\\!-\\!(A\\!-\\!\\overline{{{\\lambda}}})^{-1}]\\alpha\\Theta_{A}^{\\prime*}(\\overline{{{\\lambda}}}).\n\\]<|md_end|>\n<|box_start|>131 751 884 790<|box_end|><|ref_start|>text<|ref_end|><|md_start|>On the other hand, since the spectrum of the operator \\(A\\) is purely singular, one has the following property for all \\(u,v\\!\\in\\!H\\) as \\(\\varepsilon\\downarrow0\\) :<|md_end|>\n<|box_start|>257 796 755 815<|box_end|><|ref_start|>equation<|ref_end|><|md_start|>\\[\n\\langle[(A-k-i\\varepsilon)^{-1}-(A-k+i\\varepsilon)^{-1}]u,v\\rangle\\to0\\quad{\\mathrm{for~a.a.~}}k\\in\\mathbb{R}.\n\\]<|md_end|>\n<|box_start|>131 824 884 860<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Combining these two facts with the existence of boundary values of \\(S(\\lambda)\\) in the strong topology, it is easy to see that \\(S^{*}(k{+}i0)S(k{+}i0){=}I\\) almost everywhere on<|md_end|>"
            }
        ]
    },
    {
        "image": "s3://doc-parse-huawei/mineru2/inhouse-markdown/en-10-M/v001/images/2176bbe2c61b95b777c3ef17e8d37f05/19.jpg",
        "conversations": [
            {
                "from": "human",
                "value": "<Mineru-Image>\nGrouding with reading order: "
            },
            {
                "from": "gpt",
                "value": "\n<|box_start|>071 090 883 897<|box_end|><|ref_start|>text<|ref_end|><|md_start|>385 [19] A.H.M. Fauzi, N.A.S. Amin, R. Mat, Esterification of oleic acid to biodiesel using 386 magnetic ionic liquid: multi-objective optimization and kinetic study, Applied Energy 114 387 (2014) 809-818. 388 [20] Y. Wang, X. Wang, X. Wang, M. Liu, Z. Wu, L. Yang, S. Xia, J. Zhao, Adsorption of 389 Pb (II) from aqueous solution to Ni-doped bamboo charcoal, Journal of Industrial and 390 Engineering Chemistry 19(1) (2013) 353-359. 391 [21] X. Wang, Z. Wu, Y. Wang, W. Wang, X. Wang, Y. Bu, J. Zhao, Adsorption– 392 photodegradation of humic acid in water by using ZnO coupled TiO2/bamboo charcoal 393 under visible light irradiation, Journal of hazardous materials 262 (2013) 16-24. 394 [22] A. Bhatnagar, W. Hogland, M. Marques, M. Sillanpää, An overview of the 395 modification methods of activated carbon for its water treatment applications, Chemical 396 Engineering Journal 219 (2013) 499-511. 397 [23] X. Peng, F. Hu, F.L. Lam, Y. Wang, Z. Liu, H. Dai, Adsorption behavior and 398 mechanisms of ciprofloxacin from aqueous solution by ordered mesoporous carbon and 399 bamboo-based carbon, Journal of colloid and interface science 460 (2015) 349-360. 400 [24] S.-Y. Wang, M.-H. Tsai, S.-F. Lo, M.-J. Tsai, Effects of manufacturing conditions on 401 the adsorption capacity of heavy metal ions by Makino bamboo charcoal, Bioresource 402 Technology 99(15) (2008) 7027-7033. 403 [25] Y.-X. Chen, X.-D. Huang, Z.-Y. Han, X. Huang, B. Hu, D.-Z. Shi, W.-X. Wu, Effects 404 of bamboo charcoal and bamboo vinegar on nitrogen conservation and heavy metals 405 immobility during pig manure composting, Chemosphere 78(9) (2010) 1177-1181.<|md_end|>"
            }
        ]
    },
    {
        "image": "s3://doc-parse-huawei/mineru2/inhouse-markdown/en-10-M/v001/images/c690e1d0b39b9f17f05ec313cffeb9ec/14.jpg",
        "conversations": [
            {
                "from": "human",
                "value": "<Mineru-Image>\nGrouding with reading order: "
            },
            {
                "from": "gpt",
                "value": "\n<|box_start|>109 087 892 432<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Nutley, S. M., Walter, I., & Davies, H.T. O. (2007). Using evidence: How research can inform public services. Bristol: Policy Press. Oliver, A., & McDaid, D. (2002). Evidence-based health care: Benefits and barriers. Social Policy & Society, 1(3), 183–190. Ormerod, P. (2010). N squared: Public policy and the power of networks. London: Royal Society of Arts. Pawson, R., & Tilley, N. (1997). Realistic evaluation. London: Sage. Petticrew, M., Tugwell, P., Welch, V., Ueffing, E., Kristjansson, E., Armstrong, R., . . ., Waters, E. (2009). Cochrane update: Better evidence about wicked issues in tackling health inequities. Journal of Public Health, 31(3), 453–56. Ragin, C. (2000). Fuzzy-set social science. Chicago: University of Chicago Press. Rihoux, B., Rezso¨hazy, I., & Bol, D. (2011). Qualitative comparative analysis (QCA) in public policy analysis: An extensive review. German Policy Studies, 7(3), 9–82. de Savigny, D., & Adam, T. (2009). Systems thinking for health systems strengthening. Geneva: World Health Organization. Scho¨n, D. A., & Rein, M. (1994). Frame reflection: Toward the resolution of intractable policy controversies. New York: Basic Books. Seddon, J. (2005). Freedom from command and control: A better way to make the work work. Buckingham: Vanguard Education. Stevens, A. (2011). Telling policy stories: An ethnographic study of the use of evidence in policy-making in the UK. Journal of Social Policy, 40(2), 237–256. Tett, G. (2009, March 10). Lost through destructive creation. Financial Times, p. 11. Tomaskovic-Devey, D., & Lin, K.-H. (2011). Income dynamics, economic rents, and the financialization of the U.S. economy. American Sociological Review, 76(4), 538–559. Weiss, C. H. (1998). Evaluation. Upper Saddle River, NJ: Prentice-Hall.<|md_end|>"
            }
        ]
    },
    {
        "image": "s3://doc-parse-huawei/mineru2/inhouse-markdown/en-10-M/v001/images/5ecbc8df1ead884b4df91a498330794e/0.jpg",
        "conversations": [
            {
                "from": "human",
                "value": "<Mineru-Image>\nGrouding with reading order: "
            },
            {
                "from": "gpt",
                "value": "\n<|box_start|>088 187 441 221<|box_end|><|ref_start|>title<|ref_end|><|md_start|># 66P The TILs near solid structures is a potential prognostic factor of distant metastases in the luminal HER2-negative breast cancer<|md_end|>\n<|box_start|>088 279 487 341<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Background: The phenomenon of intratumoral morphological heterogeneity is associated with both the progression of the disease and chemosensitivity and chemoresistance. However, there are very few data about the microenvironment heterogeneity near morphological structures in breast cancer patients of various molecular subtypes. This phenomenon may underlie the failure of tumor-infiltration lymphocytes as a prognostic factor in luminal forms of breast cancer.<|md_end|>\n<|box_start|>088 345 487 397<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Methods: 152 patients with IC NST (T1e3N0e2M0) aged 29 to 75 years were enrolled in the study. The molecular subtype was determined using immunohistochemical analysis of the expression of estrogen and progesterone receptors, Ki-67 and Her2/neu. TILs were assessed in accordance with the recommendations of the International TILs Working Group<|md_end|>\n<|box_start|>088 401 487 451<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Results: It was shown that TILs near the various morphological structures is heterogeneous only in luminal Her2-negative patients. In addition, was found that the development of distant metastases and worse metastatic-free survival in this cohort of patients is associated with a high (more than \\(5\\%\\) ) TILs near solid structures and also depended on Ki-67 level.<|md_end|>\n<|box_start|>088 456 487 497<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Conclusions: TILs near solid structures is a potential prognostic factor for the development of distant metastasis in the luminal Her2-negative and Ki-67 level less \\(20\\%\\) subtype of IC NST. The study was supported by the Russian Science Foundation (grant #20-75-10033).<|md_end|>\n<|box_start|>088 584 451 619<|box_end|><|ref_start|>title<|ref_end|><|md_start|># 67TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locallyadvanced or metastatic \\(\\mathsf{H E R2+}\\) breast cancer<|md_end|>\n<|box_start|>087 628 477 650<|box_end|><|ref_start|>text<|ref_end|><|md_start|>N. Masuda1, S. Hurvitz2, L. Vahdat3, N. Harbeck4, A.C. Wolff5, S.M. Tolaney6, S. Loi7, J. O’Shaughnessy8, D. Xie9, L. Walker10, E. Rustia10, V.F. Borges1 1<|md_end|>\n<|box_start|>088 655 487 777<|box_end|><|ref_start|>text<|ref_end|><|md_start|>1Surgery and Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan; 2Medical Oncology, UCLA Medical Center / Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA; 3Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 4Breast Center, Dept. OB&GYN, LMU University Hospital, Munich, Germany; 5Breast and Ovarian Cancer Program, The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA; 6Breast Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; 7Translational Breast Cancer Genomics Lab, Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia; 8Medical Oncology, Baylor University Medical Center, Dallas, TX, USA; 9Biostatistics, Seattle Genetics, Inc., Bothell, WA, USA; 10Clinical Development, Seattle Genetics, Inc., Bothell, WA, USA; 11Medicine-Medical Oncology, University of Colorado Cancer Center, Aurora, CO, USA<|md_end|>\n<|box_start|>088 788 487 941<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Background: Tucatinib (TUC), an oral tyrosine kinase inhibitor (TKI) highly selective for HER2 with minimal inhibition of EGFR, is approved in the US for use in combination with trastuzumab (Tras) and capecitabine for treatment (tx) of patients (pts) with metastatic \\(\\mathsf{H E R2+}\\) breast cancer (MBC), including pts with brain metastases (BM), who received 1 or more prior anti-HER2-based regimens in the metastatic setting. Ado-Tras emtansine (T-DM1), approved for tx of \\(\\mathsf{H E R2+}\\) MBC after Tras and a taxane, has improved progression-free survival (PFS) and overall survival (OS). Improvements are needed, including pts with active BM. A phase Ib trial evaluated TUC ( \\(300~\\mathsf{m g}~\\mathsf{P O}\\) BID) with T-DM1 in 50 pts with \\(\\mathsf{H E R2+}\\) MBC who received prior tx with Tras and a taxane; \\(60\\%\\) of pts had BM at baseline (Borges 2018). Common AEs, mostly grade \\(_{1/2}\\) , were nausea \\((72\\%)\\) , diarrhea \\((60\\%)\\) , and fatigue \\((56\\%)\\) . Median PFS was 8.2 months and objective response rate (ORR) in pts with measurable disease \\((\\mathsf{n}{=}34)\\) was \\(47\\%\\) . Brain specific response rate (RECISTv1.1) in pts with measurable BM \\((\\mathsf{n}\\mathrm{=}14)\\) was \\(36\\%\\) . This encouraging clinical activity, including in pts with BM, provides rationale to evaluate this combination.<|md_end|>\n<|box_start|>513 241 909 948<|box_end|><|ref_start|>text<|ref_end|><|md_start|>Disclosure: N. Masuda: Honoraria (self), Research grant/Funding (self), Research grant/Funding (institution): Chugai; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self), Research grant/Funding (institution): Eli-Lilly; Honoraria (self): Takeda; Honoraria (self), Research grant/Funding (self), Research grant/Funding (institution): Eisai; Research grant/Funding (institution): Kyowa-Kirin; Research grant/ Funding (institution): MSD; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Daiichi Sankyo; Full/Part-time employment: National Hospital Organization Osaka National Hospital, Dept. of Surgery, Breast Oncology; Officer/Board of Directors: Japan Breast Cancer Research Group Association Board of Directors. S. Hurvitz: Research grant/Funding (institution): Ambryx; Research grant/Funding (institution): Amgen; Research grant/Funding (institution): Biomarin; Research grant/Funding (institution): Cascadian Therapeutics; Research grant/Funding (institution): Daiichi Sankyo; Research grant/Funding (institution): Dignitana; Research grant/Funding (institution): Genentech/Roche; Research grant/Funding (institution): GlaxoSmithKline; Research grant/Funding (institution): Immunomedics; Research grant/Funding (institution): Lilly; Research grant/Funding (institution): Macrogenics; Research grant/Funding (institution): Merrimack; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): OBI Pharma; Advisory/ Consultancy, Research grant/Funding (institution), medical writing: Pfizer; Research grant/Funding (institution): Pieris Pharma; Research grant/Funding (institution): Puma Biotech; Research grant/ Funding (institution): Radius Health; Research grant/Funding (institution): Sanofi; Research grant/ Funding (institution): Seattle Genetics; Advisory/Consultancy, medical writing: Roche; Research grant/Funding (institution): Bayer. L. Vahdat: Advisory/Consultancy, Travel/Accommodation/Expenses: Seattle Genetics, Inc.; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eisai; Advisory/Consultancy, Research grant/Funding (institution): Polyphor; Advisory/Consultancy: Berg Pharma; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Immunomedics; Research grant/Funding (institution), Other: Roche; Research grant/Funding (institution), Other: Arvinas; Research grant/Funding (institution): Polyphor; Research grant/Funding (institution): Oncotherapy Biosciences; Licensing/Royalties, A patent on bone marrow derived progenitor and relapse: No company. N. Harbeck: Advisory/Consultancy, Speaker Bureau/Expert testimony: Daiichi Sankyo; Advisory/Consultancy: Seattle Genetics, Inc.; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Officer/Board of Directors: West German Study Group. A.C. Wolff: Full/Part-time employment: John Hopkins Kimmel Cancer Center, Breast and Ovarian Cancer Program. S.M. Tolaney: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Bristol-Myers Squibb; Honoraria (self), Advisory/ Consultancy, Travel/Accommodation/Expenses: Celldex; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Eli Lilly; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Eisai; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Genentech/Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Immunomedics; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Merck; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Nektar; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Nanostring; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy: Paxman; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Puma; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Sanofi; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Seattle Genetics, Inc.; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Odonate; Honoraria (self), Advisory/Consultancy: Silverback Therapeutics; Honoraria (self), Advisory/Consultancy: G1 Therapeutics; Honoraria (self), Advisory/Consultancy: AbbVie; Honoraria (self), Advisory/Consultancy: Anthenex; Honoraria (self), Advisory/Consultancy: Oncopep; Honoraria (self), Advisory/Consultancy: Kyowa Kirin Pharmaceuticals; Honoraria (self), Advisory/Consultancy: Daiichi-Sankyo; Research grant/Funding (institution): Exelixis. S. Loi: Advisory/Consultancy: Aduro Biotech; Advisory/ Consultancy, Research grant/Funding (institution), Shareholder/Stockholder/Stock options: Novartis; Advisory/Consultancy: GlaxosmithKline; Advisory/Consultancy: G1 Therapeutics; Research grant/ Funding (institution), Shareholder/Stockholder/Stock options: Bristol-Meyers Squibb; Research grant/Funding (institution), Shareholder/Stockholder/Stock options: Merck; Research grant/Funding (institution), Shareholder/Stockholder/Stock options: Roche-Genentech; Research grant/Funding (institution): Puma Biotechnology; Research grant/Funding (institution), Shareholder/Stockholder/ Stock options: Pfizer; Research grant/Funding (institution): Eli Lilly; Advisory/Consultancy, Research grant/Funding (institution): Seattle Genetics, Inc.; Shareholder/Stockholder/Stock options: AstraZeneca. J. O’Shaughnessy: Honoraria (self): AbbVie; Honoraria (self): Agendia; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Celgene; Honoraria (self), Advisory/Consultancy, Travel/ Accommodation/Expenses: Daiichi-Sankyo; Honoraria (self): Eisai; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Genentech; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Genomic Health; Honoraria (self), Advisory/Consultancy, Travel/ Accommodation/Expenses: Grail; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/ Expenses: Heron; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Immunomedics; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ispen; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Jounce; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Lilly; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Merck; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Myriad; Honoraria (self), Advisory/<|md_end|>"
            }
        ]
    }
]